Concepedia

Flavia Ejzykowicz

FE

Statistics

Publications

11

Citations

2.4K

H-Index

11

Active since

2015

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Dana-Farber Cancer Institute

Bristol-Myers Squibb (United States)

Memorial Sloan Kettering Cancer Center

Sidney Kimmel Comprehensive Cancer Center

Flavia Ejzykowicz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, urology, and cancer therapeutics.

Top concepts

Publications per year

2015–2024

11

Publications

11

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Robert J. Motzer, David F. McDermott, Bernard Escudier et al. · Cancer · 2022 · 257 citations · Full text

Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System

Kevin M. Pantalone, Brian J. Wells, Kevin Chagin et al. · Diabetes Care · 2016 · 93 citations · Full text

Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US

Ralph P. Insinga, David J. Vanness, Josephine Feliciano et al. · Current Medical Research and Opinion · 2019 · 85 citations

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

David Cella, Robert J. Motzer, Cristina Suárez et al. · The Lancet Oncology · 2022 · 83 citations · Full text

, , +9

1–5 of 11